Biography

Dr. Bo Ning is a tenure-track Assistant Professor at Tulane University School of Medicine, with expertise in CRISPR diagnostics, extracellular vesicles, and translational nanomedicine. He has authored over 50 peer-reviewed publications in high-impact journals such as Nature Nanotechnology, Lancet Microbe, and Nature BME. His work has led to multiple patents and the development of FDA-designated breakthrough technologies, including a CRISPR-based TB blood test. Dr. Ning currently leads and contributes to several NIH-funded projects focused on infectious disease diagnostics and biomarker discovery. His research bridges molecular innovation with clinical applications, advancing next-generation tools for early detection and personalized medicine.

Expertise

TB Diagnostics
Public Health

Key Impacts

Rapid detection of drug-resistant M.tuberculosis using a multiplexed CRISPR droplet platform

Our multiplexed CRISPR droplet platform enables rapid, precise identification of drug-resistant Mtb, offering a scalable tool for clinical diagnostics and surveillance. This approach holds promise for decentralized TB testing and accelerated treatment decisions, particularly in high-burden, resource-limited settings.

Source: Conference 2024